ponatinib and blinatumomab results in high rates of cmr and ngs mrd negativity in ph-positive all
Published 1 year ago • 131 plays • Length 2:47Download video MP4
Download video MP3
Similar videos
-
6:01
ponatinib and blinatumomab for patients with philadelphia chromosome-positive all
-
1:54
ponatinib and blinatumomab for the treatment of ph all
-
1:12
ponatinib and blinatumomab in newly diagnosed ph all: subgroup analysis from phase ii study
-
5:52
a phase ii study of blinatumomab for the treatment of mrd-positive b-cell acute lymphoblastic le...
-
2:31
ponatinib & blinatumomab for ph all
-
9:21
the evolution of treatment of ph all & phase ii study of blinatumomab and ponatinib in ph all
-
3:19
blinatumomab plus ponatinib for ph all
-
5:42
interim results of a phase ii study of blinatumomab plus ponatinib for philadelphia chromosome-p...
-
1:05
comparing dasatinib-blinatumomab vs ponatinib-blinatumomab in newly diagnosed ph b-all
-
2:12
investigating the efficacy of ponatinib and blinatumomab for patients with newly diagnosed ph all
-
1:22
final results of allg all08: blinatumomab with reduced intensity chemo in older adults with b-all
-
5:58
dasatinib-blinatumomab combination for the front-line treatment of adult ph-positive all patients
-
4:17
could ponatinib blinatumomab substitute chemo allo-hsct as frontline therapy for ph all?
-
2:30
blast: blinatumomab for minimal residual disease in patients with all
-
4:40
defining ponatinib’s role in ph-positive all
-
2:32
blinatumomab and ponatinib in newly diagnosed ph all: updates from a phase ii trial
-
9:14
blinatumomab for patients with mrd-positive all
-
2:58
the neuf study: treatment of r/r philadelphia chromosome-positive all with blinatumomab
-
1:16
ponatinib for cml and ph all: five-year results from the pace trial